AstraZeneca Challenges Illinois 340B Contract Pharmacy Law in Federal Court
Key Takeaways
- AstraZeneca has sued Illinois Attorney General Kwame Raoul to block enforcement of the state's new 340B contract pharmacy law, becoming the third pharmaceutical manufacturer to challenge the law in federal court.1,2
- The dispute centers on whether Illinois may require manufacturers to provide 340B-priced drugs through covered entities' contract pharmacies and restrict manufacturers from demanding certain data as a condition of distribution.1,3
- The Illinois litigation joins a growing and increasingly divided body of federal cases testing how far states may regulate 340B contract pharmacy arrangements when the federal statute does not expressly address those relationships.2
AstraZeneca Pharmaceuticals LP has filed a federal lawsuit challenging Illinois' new 340B contract pharmacy law, adding to a growing wave of litigation over state efforts to regulate how pharmaceutical manufacturers distribute discounted drugs through the federal 340B Drug Pricing Program.1,2
The lawsuit, filed August 14, 2026, against Illinois Attorney General Kwame Raoul in the US District Court for the Northern District of Illinois, follows separate challenges filed by AbbVie and Novartis on August 7.1,2 The manufacturers contend that Illinois' Patient Access to Pharmacy Protection Act conflicts with the federal 340B framework and exceeds the state's authority to regulate the program.
The litigation places Illinois at the center of a broader legal dispute that has produced divergent outcomes in federal courts nationwide as states increasingly enact laws protecting covered entities' use of contract pharmacies.2
Illinois Law Restricts Manufacturer Limits on Contract Pharmacies
Illinois' Patient Access to Pharmacy Protection Act prohibits pharmaceutical manufacturers and other parties from denying, restricting, conditioning, or otherwise interfering with the acquisition or delivery of 340B drugs to covered entities or their authorized contract pharmacies unless receipt is prohibited by federal law.3
The law also prohibits manufacturers from restricting the number, location, ownership, or type of pharmacies that a covered entity may designate as contract pharmacies.3
In addition, manufacturers generally may not require covered entities or contract pharmacies to provide certain pricing information, implement inventory management requirements not mandated by state or federal agencies, or submit other data not required by law as a condition of receiving 340B drugs.3
The Illinois General Assembly stated that the federal 340B statute is silent regarding the distribution of 340B drugs to covered entities and their contract pharmacy partners, and characterized the regulation of drug acquisition and delivery as an area of traditional state authority.3
Violations may result in injunctive relief, damages, or civil penalties of up to $1000 for each violation. The law treats each individual 340B drug transaction subject to certain prohibited conduct as a separate violation.3
AstraZeneca Raises Federal Preemption Challenge
AstraZeneca's complaint challenges Illinois' authority to impose those requirements on manufacturers participating in the federally established 340B program.1
The manufacturer argues that the state law is preempted by federal law and conflicts with the federal statutory framework governing manufacturers' obligations under 340B.1
At the center of the dispute is a question that has surfaced repeatedly in 340B litigation: whether the federal statute requires manufacturers to facilitate 340B purchases through an unlimited number of contract pharmacies that are not themselves covered entities identified in the federal statute.
The Illinois law expressly states that it should not be construed in a manner that conflicts with applicable federal law. It also provides an exception for limited drug distribution required under federal Risk Evaluation and Mitigation Strategy requirements.3
AstraZeneca's challenge nevertheless asks the federal court to determine whether the state's contract pharmacy requirements impermissibly add to manufacturers' obligations under federal law.1
Data Restrictions Add Another Layer to the Dispute
The Illinois law's restrictions on manufacturer data requirements represent another significant compliance issue.
Manufacturers have increasingly sought claims-level information from 340B covered entities and contract pharmacies as part of efforts to identify duplicate discounts and assess program compliance. Illinois' law limits manufacturers' ability to require information beyond what state or federal law mandates as a condition of providing 340B drugs.3
At the same time, the statute contains provisions addressing duplicate discounts from the covered-entity side. Covered entities must maintain policies intended to prevent more than one 340B entity from replenishing the same pharmacy dispense and must establish processes for reimbursing manufacturers for duplicate 340B discounts they receive.3
That structure illustrates the competing compliance interests underlying the litigation: manufacturers argue that access to data is necessary to monitor program integrity, while state contract pharmacy laws seek to prevent those requirements from becoming barriers to covered entities' access to discounted drugs.
Illinois Joins Expanding National 340B Litigation
AstraZeneca's lawsuit is part of a much larger legal dispute playing out across multiple federal circuits.
According to Becker's Hospital Review, at least 21 states had enacted contract pharmacy access laws as of spring 2026. Courts have reached different conclusions when manufacturers have challenged those laws.2
The US Court of Appeals for the Eighth Circuit has upheld state 340B contract pharmacy laws in Arkansas and Missouri, while litigation involving laws in other states has produced different outcomes or remains pending. The Fourth Circuit agreed to rehear challenges involving Maryland and West Virginia en banc after earlier panel decisions favored manufacturers, while additional disputes remain active in the Ninth and Tenth Circuits.2
A similar dispute in Washington illustrates the uncertainty. AstraZeneca, AbbVie, Novartis, and the Pharmaceutical Research and Manufacturers of America challenged Washington's contract pharmacy law, but a federal district court declined to preliminarily block it in June 2026. Appeals followed.2
These differing outcomes mean that manufacturers and covered entities operating nationally may face substantially different requirements depending on jurisdiction.
Compliance Implications for Manufacturers and Covered Entities
For pharmaceutical manufacturers, the Illinois litigation highlights the increasingly complex interaction between federal 340B requirements and state-level distribution mandates.
Companies operating across multiple jurisdictions may need to evaluate state-specific requirements concerning:
- Contract pharmacy distribution;
- Claims and utilization data requests;
- Duplicate discount controls;
- Inventory management requirements; and
- Enforcement and penalty provisions.
Covered entities and contract pharmacies face their own compliance considerations. Although the Illinois law restricts certain manufacturer requirements, it also establishes reporting obligations for covered entities and requires policies designed to prevent duplicate 340B discounts.3
The law therefore does not simply regulate manufacturers; it creates a broader state-level framework governing several aspects of 340B participation and oversight.
Looking Ahead
The AstraZeneca case adds another test of how state authority intersects with a federal program whose statute does not expressly address the modern contract pharmacy model.
With AbbVie and Novartis pursuing parallel challenges in Illinois and appellate litigation continuing in several other jurisdictions, the legal boundaries surrounding state 340B contract pharmacy protections remain unsettled.2
For pharmaceutical manufacturers, covered entities, pharmacies, and compliance professionals, the growing patchwork of state laws and federal court decisions will require continued monitoring. The eventual appellate outcomes could determine whether state contract pharmacy protections become a durable component of 340B regulation or whether federal preemption places significant limits on states' ability to expand manufacturers' distribution obligations.
References
- AstraZeneca Pharmaceuticals LP v. Kwame Raoul, in his official capacity as Attorney General of the State of Illinois. Complaint. US District Court for the Northern District of Illinois. Case No. 1:26-cv-09805. Filed August 14, 2026. https://www.pacermonitor.com/public/filings/D6O45G6I/ASTRAZENECA_PHARMACEUTICALS_LP_v_KWAME_RAOUL_in_his_official_capacity__ilndce-26-09805__0001.0.pdf
- Jeffries E. Court battles leave the 340B program in legal limbo. Becker's Hospital Review. Published August 17, 2026. Accessed August 19, 2026. https://www.beckershospitalreview.com/pharmacy/court-battles-reshaping-the-340b-program/
- Illinois General Assembly. Patient Access to Pharmacy Protection Act. Public Act 104-0758. 2026. https://my.ilga.gov/ftp/Public%20Acts/104/104-0758.htm
